| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/50-1/200 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/2000-1/5000 | Human,Mouse,Rat |
| Aliases | BMP9; HHT5; BMP-9 |
| WB Predicted band size | 47 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse |
| Immunogen | Synthetic peptide of human GDF2 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是关于GDF2抗体的3篇参考文献及其摘要内容的简要概括：
---
1. **文献名称**: *"GDF2/BMP-9 as a Novel Regulator of Hepatic Functions: Insights from Antibody-Based Neutralization Studies"*
**作者**: Smith A, et al.
**摘要**: 该研究通过特异性GDF2中和抗体，揭示了GDF2在肝脏代谢和血管稳态中的调控作用。实验表明，抑制GDF2信号可减少肝星状细胞活化，提示其作为肝纤维化治疗的潜在靶点。
---
2. **文献名称**: *"Development of a High-Affinity Monoclonal Antibody Targeting GDF2 for Vascular Disease Applications"*
**作者**: Chen L, et al.
**摘要**: 报道了一种高亲和力抗GDF2单克隆抗体的开发，验证了其对血管内皮细胞中GDF2信号通路的抑制作用。该抗体在体外和动物模型中显著抑制血管异常增生，为治疗动脉粥样硬化提供了实验依据。
---
3. **文献名称**: *"GDF2 Antibody-Based Detection Reveals Its Role in Ocular Angiogenesis and Retinopathy"*
**作者**: Patel R, et al.
**摘要**: 利用抗GDF2抗体进行组织免疫组化分析，发现GDF2在糖尿病视网膜病变患者的异常血管中高表达。抗体阻断实验表明，抑制GDF2可减少病理性血管生成，支持其在眼科疾病中的治疗潜力。
---
**注**：以上文献信息为示例性内容，实际研究中请通过PubMed或Web of Science等数据库检索真实文献。
GDF2 (Growth Differentiation Factor 2), also known as BMP9 (Bone Morphogenetic Protein 9), is a member of the TGF-β superfamily involved in regulating angiogenesis, metabolic homeostasis, and tissue development. It primarily signals through the ALK1/BMPR2 receptor complex, activating SMAD1/5/8 pathways to influence endothelial cell function and vascular remodeling. GDF2 antibodies are tools designed to detect, quantify, or modulate GDF2 activity in research and therapeutic contexts.
These antibodies are widely used in immunoassays (e.g., ELISA, Western blotting) to study GDF2 expression patterns in diseases like hereditary hemorrhagic telangiectasia (HHT), pulmonary arterial hypertension, and liver fibrosis. Neutralizing GDF2 antibodies have therapeutic potential for conditions driven by excessive angiogenesis, such as cancer or retinopathies, by blocking GDF2-receptor interactions. Conversely, agonist antibodies may mimic GDF2’s protective effects in metabolic disorders, as GDF2 enhances insulin sensitivity and regulates iron metabolism.
Commercial GDF2 antibodies vary in specificity (monoclonal vs. polyclonal) and applications (research, diagnostics). Validation remains critical due to cross-reactivity risks with related BMPs. Ongoing research explores GDF2’s dual roles in vascular health and disease, positioning its antibodies as valuable reagents for both mechanistic studies and drug development.
×
